274
In vitro inhibition of CYP2C9 by zafirlukast is consistent with clinical studies showing impaired clearance of  S-warfarin and enhanced anti-thrombotic effects, although the in vitro IC(50) value is higher than the usual range of clinically relevant plasma concentrations.
 potential therapeutic event: showing 
Please tell me event type and its trigger word from given type options. Output format is "type: trigger".  Option: adverse event, potential therapeutic event 
Text: {0} 
Answer:
 potential therapeutic event: showing 